Journal
FEBS LETTERS
Volume 581, Issue 1, Pages 41-44Publisher
WILEY
DOI: 10.1016/j.febslet.2006.11.074
Keywords
EGF-receptor; EGF-receptor ligands; epigen; ADAMs; ectodomain shedding
Funding
- NIGMS NIH HHS [R01 GM64750] Funding Source: Medline
Ask authors/readers for more resources
All ligands of the epidermal growth factor receptor (EGFR), which has important roles in development and disease, are made as transmembrane precursors. Proteolytic processing by ADAMs (a disintegrin and metalloprotease) regulates the bioavailability of several EGFR-ligands, yet little is known about the enzyme responsible for processing the recently identified EGFR ligand, epigen. Here we show that ectodomain shedding of epigen requires ADAM 17, which can be stimulated by phorbol esters, phosphatase inhibitors and calcium influx. These results suggest that ADAM17 might be a good target to block the release of bioactive epigen, a highly mitogenic ligand of the EGFR which has been implicated in wound healing and cancer. (c) 2006 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available